Adoptive cell therapy against EBV-related malignancies: a survey of clinical results (Q57056125)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Adoptive cell therapy against EBV-related malignancies: a survey of clinical results (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Paola Zanovello

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Antonio Rosato

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

2

Riccardo Turrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1

Anna Merlo

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Alberto Amadori

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 September 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

12 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

1265-1294

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

Cancer; a biological approach. I. The processes of control

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus: 40 years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cellular responses to viral infection in humans: lessons from Epstein-Barr virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

EBV persistence in memory B cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus and oncogenesis: from latent genes to tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Virally targeted therapies for EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Posttransplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

CD4 T cells in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Preemptive diagnosis and treatment of Epstein-Barr virus-associated post transplant lymphoproliferative disorder after hematopoietic stem cell transplant: an approach in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

B lymphocytes and Epstein-Barr virus: the lesson of post-transplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Unsuccessful CTL transfusion in a case of post-BMT Epstein-Barr virus-associated lymphoproliferative disorder (EBV-LPD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Ex vivo generation of effective Epstein-Barr virus (EBV)-specific CD8+ cytotoxic T lymphocytes from the peripheral blood of immunocompetent Epstein Barr virus-seronegative individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Perspectives of gammadelta T cells in tumor immunology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Anti-lymphoma effect of gammadelta T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Treatment of EBV-Related Post-Renal Transplant Lymphoproliferative Disease with a Tailored Regimen Including EBV-Specific T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive immunotherapy for cancer: building on success

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Safety of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for patients with refractory EBV-related lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive immunotherapy for Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus-targeted immunotherapy for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Transduction of primary lymphocytes with Epstein-Barr virus (EBV) latent membrane protein-specific T-cell receptor induces lysis of virus-infected cells: A novel strategy for the treatment of Hodgkin's disease and nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Functional reversion of antigen-specific CD8+ T cells from patients with Hodgkin lymphoma following in vitro stimulation with recombinant polyepitope

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Increase in circulating Foxp3+CD4+CD25(high) regulatory T cells in nasopharyngeal carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Therapy of relapsed Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Clinical effects of infusing anti-Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes into patients with severe chronic active EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus-specific cytotoxic T lymphocytes from an HLA-matched sibling to a patient with severe chronic active EBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Impaired cytotoxic T lymphocyte response to Epstein-Barr virus-infected NK cells in patients with severe chronic active EBV infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Adoptive transfer of Epstein-Barr virus-specific cytotoxic T-lymphocytes for the treatment of angiocentric lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Selected amino acid change encoding Epstein-Barr virus-specific T cell epitope of the LMP2A gene in Japanese nasal NK/T cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Sequence variations of Epstein-Barr virus LMP1 gene in nasal NK/T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Treatment of Epstein-Barr-virus-associated primary CNS B cell lymphoma with allogeneic T-cell immunotherapy and stem-cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-Barr virus-associated lymphoproliferative disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cancer immunotherapy: moving beyond current vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

EBV-specific cytotoxic T lymphocytes protect against human EBV-associated lymphoma in scid mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Cytokine production and cytolytic mechanism of CD4(+) cytotoxic T lymphocytes in ex vivo expanded therapeutic Epstein-Barr virus-specific T-cell cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Epstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

A clinical development paradigm for cancer vaccines and related biologics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Preemptive Therapy of EBV-Related Lymphoproliferative Disease after Pediatric Haploidentical Stem Cell Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.9.1265

10.1517/14712598.8.9.1265

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18694349%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference